Payment overview · 2025
General Payments
$85,074.36
236 reported records · 20 companies
Healthcare provider profile · identity verified
Douglas Katsev, MD
Allopathic & Osteopathic Physicians|Ophthalmology · SANTA BARBARA, CA · NPI 1801906722
Verified facts
What the public records show
CMS Open Payments records show Douglas Katsev, MD received $85,074.36 in general payments during 2025 across 236 reported records.
Alcon Vision LLC accounted for 51.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 54 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eysuvis, Lumigan, Miebo, Oxervate, Tyrvaya, Xiidra.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LUMIGAN as an associated drug or biological on 25016 records involving 7645 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Lumigan by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VUITY as an associated drug or biological on 89 records involving 88 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Vuity by this doctor in 2024.
Alcon Vision LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported EYSUVIS as an associated drug or biological on 4201 records involving 2750 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Eysuvis by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LOTEMAX SM as an associated drug or biological on 92 records involving 67 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Lotemax Sm by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MIEBO as an associated drug or biological on 34133 records involving 12967 distinct recipient NPIs. Public Medicare Part D data also shows 146 claims for Miebo by this doctor in 2024.
Bausch & Lomb Americas Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIIDRA as an associated drug or biological on 28163 records involving 11019 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Xiidra by this doctor in 2024.
Dompe US, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OXERVATE as an associated drug or biological on 19540 records involving 9712 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Oxervate by this doctor in 2024.
Harrow Eye, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TOBRADEX ST as an associated drug or biological on 50 records involving 48 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Tobradex St by this doctor in 2024.
Oyster Point Pharma, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TYRVAYA as an associated drug or biological on 8925 records involving 5041 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Tyrvaya by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Alcon Vision LLC | Unresolved — no canonical attribution shown | $43,518.44 | 51.1% | 56 | 2025 |
| Bausch & Lomb Americas Inc. | Unresolved — no canonical attribution shown | $34,203.95 | 40.2% | 56 | 2025 |
| Apellis Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $1,632.50 | 1.9% | 1 | 2025 |
| Glaukos Corporation | Unresolved — no canonical attribution shown | $1,386.18 | 1.6% | 9 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $1,196.28 | 1.4% | 8 | 2025 |
| Harrow Eye, LLC | Unresolved — no canonical attribution shown | $965.39 | 1.1% | 27 | 2025 |
| Tarsus Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $320.97 | 0.4% | 9 | 2025 |
| SUN PHARMACEUTICAL INDUSTRIES INC. | Unresolved — no canonical attribution shown | $290.62 | 0.3% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $275.09 | 0.3% | 18 | 2025 |
| Dompe US, Inc. | Unresolved — no canonical attribution shown | $245.54 | 0.3% | 7 | 2025 |
| ANI Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $210.91 | 0.2% | 14 | 2025 |
| Johnson & Johnson Surgical Vision, Inc. | Unresolved — no canonical attribution shown | $191.64 | 0.2% | 4 | 2025 |
| Nova Eye, Inc. | Unresolved — no canonical attribution shown | $169.94 | 0.2% | 1 | 2025 |
| LEICA MICROSYSTEMS INC. | Unresolved — no canonical attribution shown | $89.37 | 0.1% | 2 | 2025 |
| RxSight Inc | Unresolved — no canonical attribution shown | $86.61 | 0.1% | 2 | 2025 |
| Ocular Therapeutix, Inc. | Unresolved — no canonical attribution shown | $83.52 | 0.1% | 4 | 2025 |
| NEW WORLD MEDICAL,INC. | Unresolved — no canonical attribution shown | $65.79 | 0.1% | 4 | 2025 |
| Merz Pharmaceuticals, LLC | Unresolved — no canonical attribution shown | $61.14 | 0.1% | 2 | 2025 |
| Oyster Point Pharma, Inc. | Unresolved — no canonical attribution shown | $60.80 | 0.1% | 2 | 2025 |
| Johnson & Johnson Vision Care, Inc. | Unresolved — no canonical attribution shown | $19.68 | 0.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Consulting Fee | $34,557.50 | 9 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $23,000.00 | 4 |
| Compensation for serving as faculty or as a speaker for a medical education program | $13,200.00 | 5 |
| Food and Beverage | $7,443.90 | 182 |
| Travel and Lodging | $6,872.96 | 36 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TRYPTYR Normalized: tryptyr |
Drug | Alcon Vision LLC | $41,952.32 | 38 | 2025 |
Source payment records
|
|||||
| MIEBO Normalized: miebo |
Drug | Bausch & Lomb Americas Inc. | $20,004.96 | 42 | 2025 |
Source payment records
|
|||||
| XIIDRA Normalized: xiidra |
Drug | Bausch & Lomb Americas Inc. | $19,782.02 | 37 | 2025 |
Source payment records
|
|||||
| enVista MX60 IOL Normalized: envista mx60 iol |
Device | Bausch & Lomb Americas Inc. | $14,164.37 | 5 | 2025 |
Source payment records
|
|||||
| Crystalens Accommodating IOL (AT-52AO) Normalized: crystalens accommodating iol at 52ao |
Device | Bausch & Lomb Americas Inc. | $11,945.95 | 3 | 2025 |
Source payment records
|
|||||
| STELLARIS ELITE Normalized: stellaris elite |
Device | Bausch & Lomb Americas Inc. | $11,945.95 | 3 | 2025 |
Source payment records
|
|||||
| Trulign IOL Normalized: trulign iol |
Device | Bausch & Lomb Americas Inc. | $11,945.95 | 3 | 2025 |
Source payment records
|
|||||
| Syfovre Normalized: syfovre |
Drug | Apellis Pharmaceuticals, Inc. | $1,632.50 | 1 | 2025 |
Source payment records
|
|||||
| KXL System Normalized: kxl system |
Device | Glaukos Corporation | $1,200.00 | 1 | 2025 |
Source payment records
|
|||||
| DURYSTA Normalized: durysta |
Drug | ABBVIE INC. | $944.24 | 3 | 2025 |
Source payment records
|
|||||
| VEVYE Normalized: vevye |
Drug | Harrow Eye, LLC | $503.02 | 19 | 2025 |
Source payment records
|
|||||
| HYDRUS Microstent Normalized: hydrus microstent |
Device | Alcon Vision LLC | $338.43 | 6 | 2025 |
Source payment records
|
|||||
| XDEMVY Normalized: xdemvy |
Drug | Tarsus Pharmaceuticals, Inc. | $320.97 | 9 | 2025 |
Source payment records
|
|||||
| Cequa Normalized: cequa |
Drug | SUN PHARMACEUTICAL INDUSTRIES INC. | $290.62 | 9 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $275.09 | 18 | 2025 |
Source payment records
|
|||||
| OXERVATE Normalized: oxervate |
Drug | Dompe US, Inc. | $245.54 | 7 | 2025 |
Source payment records
|
|||||
| PURIFIED CORTROPHIN GEL Normalized: purified cortrophin gel |
Drug | ANI Pharmaceuticals, Inc. | $210.91 | 14 | 2025 |
Source payment records
|
|||||
| Centurion Normalized: centurion |
Device | Alcon Vision LLC | $199.99 | 1 | 2025 |
Source payment records
|
|||||
| enVista Envy IOL Normalized: envista envy iol |
Device | Bausch & Lomb Americas Inc. | $180.65 | 4 | 2025 |
Source payment records
|
|||||
| IHEEZO Normalized: iheezo |
Drug | Harrow Eye, LLC | $177.63 | 4 | 2025 |
Source payment records
|
|||||
| KXL system (not refurbished) Normalized: kxl system not refurbished |
Device | Glaukos Corporation | $143.37 | 6 | 2025 |
Source payment records
|
|||||
| TECNIS IOL Normalized: tecnis iol |
Device | Johnson & Johnson Surgical Vision, Inc. | $136.75 | 3 | 2025 |
Source payment records
|
|||||
| LUMIGAN Normalized: lumigan |
Drug | ABBVIE INC. | $134.16 | 1 | 2025 |
Source payment records
|
|||||
| STELLARIS Normalized: stellaris |
Device | Bausch & Lomb Americas Inc. | $131.53 | 1 | 2025 |
Source payment records
|
|||||
| VYZULTA Normalized: vyzulta |
Drug | Bausch & Lomb Americas Inc. | $129.13 | 1 | 2025 |
Source payment records
|
|||||
| Clareon Normalized: clareon |
Device | Alcon Vision LLC | $96.95 | 3 | 2025 |
Source payment records
|
|||||
| XEN GLAUCOMA TREATMENT SYSTEM Normalized: xen glaucoma treatment system |
Device | ABBVIE INC. | $90.80 | 1 | 2025 |
Source payment records
|
|||||
| LIGHT ADJUSTABLE LENS (LAL) Normalized: light adjustable lens lal |
Device | RxSight Inc | $86.61 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT CONTACT LENS Normalized: rxsight contact lens |
Device | RxSight Inc | $86.61 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR CARTRIDGE Normalized: rxsight injector cartridge |
Device | RxSight Inc | $86.61 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT INJECTOR HANDPIECE Normalized: rxsight injector handpiece |
Device | RxSight Inc | $86.61 | 2 | 2025 |
Source payment records
|
|||||
| RXSIGHT LIGHT DELIVERY DEVICE (LDD) Normalized: rxsight light delivery device ldd |
Device | RxSight Inc | $86.61 | 2 | 2025 |
Source payment records
|
|||||
| DEXTENZA Normalized: dextenza |
Drug | Ocular Therapeutix, Inc. | $83.52 | 4 | 2025 |
Source payment records
|
|||||
| VERITAS Vision System Normalized: veritas vision system |
Device | Johnson & Johnson Surgical Vision, Inc. | $77.56 | 1 | 2025 |
Source payment records
|
|||||
| Ahmed Glaucoma Valve Normalized: ahmed glaucoma valve |
Device | NEW WORLD MEDICAL,INC. | $65.79 | 4 | 2025 |
Source payment records
|
|||||
| Clearpath Normalized: clearpath |
Device | NEW WORLD MEDICAL,INC. | $65.79 | 4 | 2025 |
Source payment records
|
|||||
| Kahook Dual Blade Normalized: kahook dual blade |
Device | NEW WORLD MEDICAL,INC. | $65.79 | 4 | 2025 |
Source payment records
|
|||||
| Streamline Normalized: streamline |
Device | NEW WORLD MEDICAL,INC. | $65.79 | 4 | 2025 |
Source payment records
|
|||||
| Via360 Normalized: via360 |
Device | NEW WORLD MEDICAL,INC. | $65.79 | 4 | 2025 |
Source payment records
|
|||||
| Xeomin Normalized: xeomin |
Biological | Merz Pharmaceuticals, LLC | $61.14 | 2 | 2025 |
Source payment records
|
|||||
| RYZUMVI Normalized: ryzumvi |
Drug | Oyster Point Pharma, Inc. | $60.80 | 2 | 2025 |
Source payment records
|
|||||
| TYRVAYA Normalized: tyrvaya |
Drug | Oyster Point Pharma, Inc. | $60.80 | 2 | 2025 |
Source payment records
|
|||||
| AMO PHACO NEEDLE Normalized: amo phaco needle |
Device | Johnson & Johnson Surgical Vision, Inc. | $54.89 | 1 | 2025 |
Source payment records
|
|||||
| iDoseTR Normalized: idosetr |
Drug | Glaukos Corporation | $42.81 | 2 | 2025 |
Source payment records
|
|||||
| XIPERE Normalized: xipere |
Drug | Bausch & Lomb Americas Inc. | $39.07 | 1 | 2025 |
Source payment records
|
|||||
| UNITY Normalized: unity |
Device | Alcon Vision LLC | $38.63 | 1 | 2025 |
Source payment records
|
|||||
| EYSUVIS Normalized: eysuvis |
Drug | Alcon Vision LLC | $33.12 | 1 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $27.08 | 3 | 2025 |
Source payment records
|
|||||
| Rocklatan Normalized: rocklatan |
Drug | Alcon Vision LLC | $26.42 | 1 | 2025 |
Source payment records
|
|||||
| Clareon PanOptix Pro Normalized: clareon panoptix pro |
Device | Alcon Vision LLC | $26.05 | 1 | 2025 |
Source payment records
|
|||||
| Photrexa Viscous and Photrexa Normalized: photrexa viscous and photrexa |
Drug | Glaukos Corporation | $25.06 | 2 | 2025 |
Source payment records
|
|||||
| ScoutPro Osmolarity System Normalized: scoutpro osmolarity system |
Device | Bausch & Lomb Americas Inc. | $24.11 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $15.23 | 2 | 2025 |
Source payment records
|
|||||
| enVista Aspire IOL Normalized: envista aspire iol |
Device | Bausch & Lomb Americas Inc. | $6.40 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| EYSUVIS eysuvis |
2025 | Eysuvis | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LUMIGAN lumigan |
2025 | Lumigan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MIEBO miebo |
2025 | Miebo | 2024 | 146 | exact normalized | Medicare Part D |
| OXERVATE oxervate |
2025 | Oxervate | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TYRVAYA tyrvaya |
2025 | Tyrvaya | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XIIDRA xiidra |
2025 | Xiidra | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LUMIGAN open payments reported associated product |
CMS Open Payments — General Payments 25016 supporting records · 7645 recipient NPIs · example record 1201352548 |
Lumigan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VUITY open payments reported associated product |
CMS Open Payments — General Payments 89 supporting records · 88 recipient NPIs · example record 1201354767 |
Vuity · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| Alcon Vision LLC Exact reporting entity; no affiliate inference |
2025 | EYSUVIS open payments reported associated product |
CMS Open Payments — General Payments 4201 supporting records · 2750 recipient NPIs · example record 1207357018 |
Eysuvis · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | LOTEMAX SM open payments reported associated product |
CMS Open Payments — General Payments 92 supporting records · 67 recipient NPIs · example record 1254732081 |
Lotemax Sm · 2024 Exact normalized brand match · 1 Part D row |
40 | 17 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | MIEBO open payments reported associated product |
CMS Open Payments — General Payments 34133 supporting records · 12967 recipient NPIs · example record 1254730224 |
Miebo · 2024 Exact normalized brand match · 1 Part D row |
146 | 51 |
| Bausch & Lomb Americas Inc. Exact reporting entity; no affiliate inference |
2025 | XIIDRA open payments reported associated product |
CMS Open Payments — General Payments 28163 supporting records · 11019 recipient NPIs · example record 1254730224 |
Xiidra · 2024 Exact normalized brand match · 1 Part D row |
61 | 32 |
| Dompe US, Inc. Exact reporting entity; no affiliate inference |
2025 | OXERVATE open payments reported associated product |
CMS Open Payments — General Payments 19540 supporting records · 9712 recipient NPIs · example record 1248849978 |
Oxervate · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| Harrow Eye, LLC Exact reporting entity; no affiliate inference |
2025 | TOBRADEX ST open payments reported associated product |
CMS Open Payments — General Payments 50 supporting records · 48 recipient NPIs · example record 1236210819 |
Tobradex St · 2024 Exact normalized brand match · 1 Part D row |
13 | 11 |
| Oyster Point Pharma, Inc. Exact reporting entity; no affiliate inference |
2025 | TYRVAYA open payments reported associated product |
CMS Open Payments — General Payments 8925 supporting records · 5041 recipient NPIs · example record 1238388111 |
Tyrvaya · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Doxycycline Monohydrate | Doxycycline Monohydrate | 187 | 145 |
| Miebo | Perfluorohexyloctane/Pf | 146 | 51 |
| Prednisolone Acetate | Prednisolone Acetate | 138 | 73 |
| Timolol Maleate | Timolol Maleate | 121 | 55 |
| Ofloxacin | Ofloxacin | 109 | 69 |
| Neomycin-Polymyxin-Dexameth | Neomycin/Polymyxin B/Dexametha | 65 | 36 |
| Xiidra | Lifitegrast | 61 | 32 |
| Ketorolac Tromethamine | Ketorolac Tromethamine | 50 | 34 |
| Latanoprost | Latanoprost | 48 | 20 |
| Zylet | Tobramycin/Lotepred Etab | 46 | 35 |
| Acyclovir | Acyclovir | 44 | 13 |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 42 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 41 | 22 |
| Lotemax Sm | Loteprednol Etabonate | 40 | 17 |
| Erythromycin | Erythromycin Base | 28 | 21 |
| Doxycycline Hyclate | Doxycycline Hyclate | 27 | 15 |
| Loteprednol Etabonate | Loteprednol Etabonate | 26 | 17 |
| Oxervate | Cenegermin-Bkbj | 24 | suppressed |
| Restasis | Cyclosporine | 24 | 15 |
| Besivance | Besifloxacin Hcl | 21 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 19 | 18 |
| Tobramycin-Dexamethasone | Tobramycin/Dexamethasone | 17 | 14 |
| Acetazolamide Er | Acetazolamide | 16 | 13 |
| Eysuvis | Loteprednol Etabonate | 14 | suppressed |
| Cyclosporine | Cyclosporine | 13 | suppressed |
| Lumigan | Bimatoprost | 13 | suppressed |
| Tobradex St | Tobramycin/Dexamethasone | 13 | 11 |
| Vuity | Pilocarpine Hcl | 12 | suppressed |
| Gabapentin | Gabapentin | 11 | suppressed |
| Tyrvaya | Varenicline Tartrate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $85,074.36 · 236 records | Alcon Vision LLC | AMO PHACO NEEDLE, Ahmed Glaucoma Valve, BOTOX, Centurion, Cequa, Clareon, Clareon PanOptix Pro, Clearpath, Crystalens Accommodating IOL (AT-52AO), DEXTENZA, DURYSTA, EYSUVIS, HYDRUS Microstent, IHEEZO, KXL System, KXL system (not refurbished), Kahook Dual Blade, LIGHT ADJUSTABLE LENS (LAL), LUMIGAN, MIEBO, OXERVATE, PURIFIED CORTROPHIN GEL, Photrexa Viscous and Photrexa, QULIPTA, RXSIGHT CONTACT LENS, RXSIGHT INJECTOR CARTRIDGE, RXSIGHT INJECTOR HANDPIECE, RXSIGHT LIGHT DELIVERY DEVICE (LDD), RYZUMVI, Rocklatan, STELLARIS, STELLARIS ELITE, ScoutPro Osmolarity System, Streamline, Syfovre, TECNIS IOL, TEPEZZA, TRYPTYR, TYRVAYA, Trulign IOL, UNITY, VERITAS Vision System, VEVYE, VYZULTA, Via360, XDEMVY, XEN GLAUCOMA TREATMENT SYSTEM, XIIDRA, XIPERE, Xeomin, enVista Aspire IOL, enVista Envy IOL, enVista MX60 IOL, iDoseTR | 9 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eysuvis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error